Ahmet Dirican, Professor of Medical Oncology at Medicana International İzmir Hospital, shared on X:
“A new post-immunotherapy option in advanced ccRCC.
FDA has approved belzutifan + lenvatinib following prior PD-1/PD-L1 therapy, based on the phase III LITESPARK-011 trial.
- PFS: 14.8 vs 10.7 months; HR 0.70
- ORR: 52.6% vs 40.2%
- DoR: 23.0 vs 12.3 months
An important step forward – but with perspective: OS benefit is not yet statistically significant (HR 0.85) and grade ≥3 toxicity remains high (~84%).
A promising new standard after IO, with patient selection and toxicity management remaining crucial.”
You can also read:
FDA Approved Belzutifan Plus Lenvatinib in Advanced ccRCC
